Connect
MJA
MJA

Palliative radiotherapy for bone metastases at the end of life in Victoria

Wee Loon Ong, Farshad Foroudi, Roger L Milne and Jeremy L Millar
Med J Aust 2021; 214 (5): . || doi: 10.5694/mja2.50954
Published online: 15 March 2021

To the Editor: Palliative radiotherapy is effective for symptomatic management of bone metastases in cancer patients. However, it may take 2–4 weeks after completion of radiotherapy to achieve maximal clinical response.1 Radiotherapy can be delivered as a single fraction treatment (SFRT), or over a more protracted course of multifraction treatment (MFRT).2 Randomised trials have consistently shown that SFRT and MFRT provide equally effective symptom control,3 and SFRT is associated with lower medical and societal cost,4 allowing for better health services utilisation. Hence, in patients with poor prognosis, the use of SFRT over MFRT should be encouraged to minimise the time patients spend on treatment at the end of life without compromising efficacy.

  • Wee Loon Ong1,2
  • Farshad Foroudi1
  • Roger L Milne3,4
  • Jeremy L Millar5,6

  • 1 Olivia Newton‐John Cancer and Wellness Centre, Austin Health, Melbourne, VIC
  • 2 University of Cambridge, Cambridge, UK
  • 3 Cancer Council Victoria, Melbourne, VIC
  • 4 Centre for Epidemiology and Biostatistics, University of Melbourne, Melbourne, VIC
  • 5 Alfred Health, Melbourne, VIC
  • 6 Monash University, Melbourne, VIC

Correspondence: weeloonong@cantab.net

Acknowledgements: 

We thank the Centre for Victorian Data Linkage for performing data linkages and providing access to the dataset.

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.